Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
This perspective article proposes various synergies between mindfulness practice and psychedelics. The authors argue that psychedelics can form the compass (direction setting) and mindfulness the vehicle (integration).
Authors
- Paul Liknaitzky
- Richard Chambers
Published
Abstract
Psychedelic and mindfulness interventions have been shown to improve mental ill-health and wellbeing, with a range of clinical processes and effects in common. However, each appear to contain specific challenges in the context of mental health treatment. In this Perspective, we focus on a set of distinct affordances, “useful differences”, within psychedelic and mindfulness interventions that might address common challenges within the other intervention. Accordingly, we propose a set of applied synergies, indicating specific ways in which these two promising interventions might be combined for greater benefit. Metaphorically, on the journey toward mental health and wellbeing, we propose that psychedelic treatments may serve the role of Compass (initiating, motivating, and steering the course of mindfulness practice), with mindfulness interventions serving the role of Vehicle (integrating, deepening, generalizing, and maintaining the novel perspectives and motivation instigated by psychedelic experience). We outline a set of testable hypotheses and future research associated with the synergistic action of psychedelic and mindfulness interventions toward improved clinical outcomes.
Research Summary of 'Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice'
Introduction
Mindfulness meditation (MM) and psychedelic-assisted psychotherapy (PP) have each been shown to improve mental health and wellbeing, yet they differ in mechanisms, clinical profiles, and practical challenges. Earlier research summarised in this Perspective notes that mindfulness-based interventions (MBIs) produce small to moderate symptom reductions for psychiatric disorders at post-treatment (d = 0.23; d = 0.35 versus active and nonactive comparators) and at 6 month follow-up (d = 0.29; d = 0.52). Classical psychedelics (serotonergic tryptamines such as psilocybin, LSD, and ayahuasca) reliably induce profound nonordinary states of consciousness, with acute mystical-type and challenging experiences that appear to predict subsequent clinical change. Neurobiological and phenomenological overlaps are reported between MM and psychedelics (for example, reduced Default Mode Network activation and altered self-experience), but important practical limitations exist for each: MBIs struggle with engagement and sustained practice, while psychedelic effects can be robust yet transient and trials face methodological constraints (small samples, expectancy effects, variable psychotherapeutic support).
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Authors
- APA Citation
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021). Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice. ACS Pharmacology & Translational Science, 4(2), 416-423. https://doi.org/10.1021/acsptsci.1c00034
References (46)
Papers cited by this study that are also in Blossom
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Show all 46 referencesShow fewer
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Madsen, M. K., Fisher, P. M., Stenbæk, D. S. et al. · European Neuropsychopharmacology (2020)
Uthaug, M. V., Lancelotta, R., van Oorsouw, K. et al. · Psychopharmacology (2019)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Speth, J., Speth, C., Kaelen, M. et al. · Journal of Psychopharmacology (2016)
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Hendricks, P. S. · International Review of Psychiatry (2018)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Van Mulukom, V., Patterson, R. E., Van Elk, M. · Psychopharmacology (2020)
Pokorny, T., Preller, K. H., Kometer, M. et al. · International Journal of Neuropsychopharmacology (2017)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Agin-Liebes, G. I., Malone, T., Yalch, M. M. et al. · Journal of Psychopharmacology (2020)
Cited By (27)
Papers in Blossom that reference this study
Schlomberg, J. T. T., Meling, D., Grylka, R. et al. · Scientific Reports (2026)
Fabiano, N., Stubbs, B., Lawrence, D. W. et al. · Discover Mental Health (2026)
Lewis, B. R., Hendrick, J., Byrne, K. et al. · PLOS Medicine (2025)
McAlpine, R., Kamboj, S. K. · Scientific Reports (2024)
Meling, D., Egger, K., Aicher, H. D. et al. · Journal of Psychopharmacology (2024)
Jiwani, Z., Goldberg, S. B., Stroud, J. et al. · MedRvix (2024)
Gent, E. M., Bryan, J. W., Cleary, M. A. et al. · Journal of Psychopharmacology (2024)
Tap, S. C. · Addiction Biology (2024)
Berit, S., Meling, D., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Show all 27 papersShow fewer
Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)
Simonsson, O., Osika, W., Stenfors, C. U. D. et al. · Psychological Medicine (2023)
Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)
Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)
Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)
Simonsson, A., Simonsson, O., Chambers, R. et al. · Mindfulness (2023)
Simonds, C. H. · Journal of Psychedelic Studies (2023)
Radakovic, C., Radakovic, R., Peryer, G. et al. · Journal of Psychedelic Studies (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Earleywine, M., Low, F., Lau, C. et al. · Journal of Humanistic Psychology (2022)
Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)
Simonsson, O., Goldberg, S. B. · Journal of Psychoactive Drugs (2022)
Lewis-Healey, E., Laukkonen, R., Van Elk, M. · Psyarxiv (2021)
Olson, D. E. · ACS Pharmacology and Translational Science (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.